leflunomide has been researched along with Immunoglobulin G4-Related Disease in 6 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Immunoglobulin G4-Related Disease: A spectrum of systemic autoimmune diseases in which IMMUNOGLOBULIN G4 plays a pathophysiologic role. It can affect multiple organs in highly variable presentations, characterized by inflammatory lesions composed of IgG4-positive PLASMA CELLS, further infiltrated by T helper cells (T-LYMPHOCYTES, HELPER-INDUCER) when linked to progressive FIBROSIS and eventual organ damage.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Results of in-vitro studies on Janus kinase (JAK)/signal transducers and activators of transcription and mammalian target of rapamycin (mTOR) pathways, comparative studies with leflunomide as an induction therapy, and a long-term follow-up study with tocilizumab may contribute to the management of Takayasu arteritis." | 5.12 | Aortitis: an update. ( Erdogan, M, 2021) |
| " All patients received GCs with a predefined taper regimen starting from a dosage of 0." | 2.94 | Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial. ( Dong, C; Gao, D; Huang, F; Ji, X; Jin, J; Li, K; Li, Y; Liao, S; Luo, G; Wang, H; Wang, X; Wang, Y; Zhang, J; Zhang, Y; Zhao, Y; Zhao, Z; Zhu, J, 2020) |
| " Clinical data at baseline and after treatment, treatment response, relapse rate, and adverse effects were recorded and analyzed." | 1.91 | Comparison of the efficacy and safety of leflunomide versus mycophenolate mofetil in treating IgG4-related disease: a retrospective cohort study. ( Chen, Y; Fei, Y; Li, J; Li, R; Liu, Z; Lu, H; Luo, X; Peng, L; Peng, Y; Wu, T; Zeng, X; Zhang, W; Zhao, Y; Zhou, J, 2023) |
| " Clinical manifestation, IgG4-RD responder index (IgG-RD RI), serological indexes, gland ultrasound findings, and adverse drug effect were recorded." | 1.56 | Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease. ( Bian, W; Chen, D; Chen, J; Fu, J; Li, Y; Li, Z; Liu, Y; Sun, X; Zhang, W; Zhang, Y; Zhao, X, 2020) |
| "We prospectively enrolled 215 newly diagnosed patients with IgG4-RD, who were initially treated with glucocorticoid (GC) alone or in combination with immunosuppressive agents (IM), and had at least 6 months of follow up." | 1.48 | Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. ( Fei, Y; Feng, R; Lai, Y; Peng, L; Wang, L; Wang, M; Zeng, X; Zhang, F; Zhang, P; Zhang, W; Zhang, X; Zhao, Y, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Y | 2 |
| Zhao, Z | 2 |
| Gao, D | 2 |
| Wang, H | 2 |
| Liao, S | 2 |
| Luo, G | 2 |
| Ji, X | 2 |
| Li, Y | 3 |
| Wang, X | 2 |
| Zhao, Y | 4 |
| Li, K | 2 |
| Zhang, J | 4 |
| Jin, J | 2 |
| Zhang, Y | 3 |
| Zhu, J | 2 |
| Huang, F | 2 |
| Chen, Y | 1 |
| Li, R | 1 |
| Luo, X | 1 |
| Wu, T | 1 |
| Li, J | 1 |
| Liu, Z | 1 |
| Peng, Y | 1 |
| Lu, H | 1 |
| Peng, L | 2 |
| Zhou, J | 1 |
| Zeng, X | 2 |
| Fei, Y | 2 |
| Zhang, W | 3 |
| Liu, Y | 1 |
| Bian, W | 1 |
| Fu, J | 1 |
| Sun, X | 1 |
| Chen, D | 1 |
| Chen, J | 1 |
| Zhao, X | 1 |
| Li, Z | 1 |
| Dong, C | 1 |
| Erdogan, M | 1 |
| Wang, L | 1 |
| Zhang, P | 1 |
| Wang, M | 1 |
| Feng, R | 1 |
| Lai, Y | 1 |
| Zhang, X | 1 |
| Zhang, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study of Safety and Efficacy of Leflunomide for Maintenance of Remission in IgG4 Related Disease[NCT02703194] | Phase 4 | 68 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for leflunomide and Immunoglobulin G4-Related Disease
| Article | Year |
|---|---|
Aortitis: an update.
Topics: Antibodies, Monoclonal, Humanized; Aorta; Aortitis; Female; Follow-Up Studies; Giant Cell Arteritis; | 2021 |
1 trial available for leflunomide and Immunoglobulin G4-Related Disease
| Article | Year |
|---|---|
Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial.
Topics: Drug Therapy, Combination; Glucocorticoids; Humans; Immunoglobulin G4-Related Disease; Immunosuppres | 2020 |
4 other studies available for leflunomide and Immunoglobulin G4-Related Disease
| Article | Year |
|---|---|
Clinical value of plasmablasts in predicting disease relapse in patients with IgG4-related disease.
Topics: Chronic Disease; Humans; Immunoglobulin G; Immunoglobulin G4-Related Disease; Leflunomide; Plasma Ce | 2023 |
Comparison of the efficacy and safety of leflunomide versus mycophenolate mofetil in treating IgG4-related disease: a retrospective cohort study.
Topics: Drug Therapy, Combination; Glucocorticoids; Humans; Immunoglobulin G4-Related Disease; Immunosuppres | 2023 |
Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease.
Topics: Adult; Aged; Chromones; Cyclophosphamide; Female; Glucocorticoids; Humans; Immunoglobulin G; Immunog | 2020 |
Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Child; Cohort Studies; Cyclophosphamide; C | 2018 |